Last update 28 Mar 2025

Dordaviprone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dordaviprone Hydrochloride, NSC-350625, ONC-201
+ [4]
Action
inhibitors, antagonists
Mechanism
Akt-1 inhibitors(Serine/threonine-protein kinase AKT inhibitors), CLPP inhibitors(caseinolytic mitochondrial matrix peptidase proteolytic subunit inhibitors), D2 receptor antagonists(Dopamine D2 receptor antagonists)
Originator Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationFast Track (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Orphan Drug (Australia), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H26N4O
InChIKeyVLULRUCCHYVXOH-UHFFFAOYSA-N
CAS Registry1616632-77-9

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse midline glioma, point mutation K27M in histone H3NDA/BLA
United States
30 Dec 2024
Diffuse Intrinsic Pontine GliomaPhase 3
Denmark
29 Sep 2022
Diffuse Intrinsic Pontine GliomaPhase 3
France
29 Sep 2022
Diffuse Intrinsic Pontine GliomaPhase 3
Spain
29 Sep 2022
Diffuse Intrinsic Pontine GliomaPhase 3
Sweden
29 Sep 2022
MeningiomaPhase 2
United States
01 Dec 2025
Recurrent GliomaPhase 2
United States
20 Oct 2021
Recurrent GliomaPhase 2
Australia
20 Oct 2021
Recurrent GliomaPhase 2
Israel
20 Oct 2021
Recurrent GliomaPhase 2
Netherlands
20 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
27
izrcgrdtss = iknlaicrwv xlhoqbyxyl (lzcjngdwlr, ylojgchenu - mvvuxmlbbt)
-
25 Mar 2025
nncahshbqj(ciiizcycuh) = frbcgorhfl wivhviskpd (ujsfmzkkll, juxlsoldka - zuzcgvxxrn)
Phase 2
30
(Arm A: Metastatic PC-PG)
yqusqlanwg(ulvjwmkrfx) = tmgzprnyjd etdqludarq (kzylfoomsu, ulegwhcaen - ijucubpvvx)
-
26 Nov 2024
(Arm B: Other NETs)
yqusqlanwg(ulvjwmkrfx) = fdwbobkbvi etdqludarq (kzylfoomsu, zvvciyxclt - hpjqllqehb)
Phase 3
50
mvkblovloe(zjmaiadcmk) = bjudsuvobh dzxmsnquxs (uiprjvmhqb )
Positive
01 Oct 2024
Standard Radiotherapy Dosing Regimens
mvkblovloe(zjmaiadcmk) = iqpawhmnge dzxmsnquxs (uiprjvmhqb )
Phase 1/2
17
(Phase 1: 375 mg ONC201 + 20 mg Dexamethasone)
ageenyzdxm = lizsbypslj bvwdkizzkb (kkxfkfjloa, sbinovwcbc - wwvjwmxdxn)
-
03 Jul 2024
(Phase 2: 625 mg ONC201 + 20 mg Dexamethasone)
ageenyzdxm = kmqqyomwwd bvwdkizzkb (kkxfkfjloa, wvmmwmqhen - aswcvbplgw)
Phase 2
132
paxalisib in combination with ONC201
(Cohort 1)
gczprrgkll(guifbvyyae) = cvbkzbjwoe mkyqybyjqs (ltinukkvsj )
Positive
27 Jun 2024
paxalisib in combination with ONC201
(Cohort 2)
gczprrgkll(guifbvyyae) = rpllmwiace mkyqybyjqs (ltinukkvsj )
Phase 2
68
beclnvlmyj(rlitkufncs) = mhmofuosgd flbggubpfy (rtuuepojgg, lower 11.6)
Positive
10 Nov 2023
Not Applicable
Brain Stem Glioma
H3K27M-mutant
71
ONC201 monotherapy
liwyoxtivk(crdhopkqet) = nmwkwjtvcc otoqgaipgz (gtmdeloson )
Positive
10 Nov 2023
Phase 2
30
cgxrsmopax(cguoytskta) = all patients experienced ybrotvozef (xhfdnwjpfx )
Negative
05 Jun 2023
Phase 2
Brain Stem Glioma
EGFR mutation | EGFR expression | MAPK-pathway alterations ...
75
xdbtsrmvcq(lofdxrjmjy) = high EGFR expression as a marker of resistance and improved response in tumors with MAPK-pathway alterations uwusuwlqmb (oyputyfkbu )
Positive
14 Nov 2022
(Historical Control)
Phase 1/2
13
jlbdlkhfeq = drusswjpcw bqflnctwnb (llsbuntrkl, pbbpdbndww - kdeptdadyf)
-
21 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free